Jane Axelrad, FDA’s associate director of CDER at the time, wrote that, “we
usually find ourselves dealing with situations where sponsors want to minimize
the risk information.” According to Axelrad, preemption wouldn’t be “consistent
with the agency’s role in protecting the public health.” …